NEW YORK (GenomeWeb News) — Quest Diagnostics has licensed from Pathway Diagnostics the underlying technology used in its co-receptor tropism HIV assay, Quest said today.
 
The non-exclusive license covers the heteroduplex tracking technology used in Pathway’s SensiTrop test. Quest said that a molecular-based assay for co-receptor tropism will help physicians personalize HIV therapy.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.